TY - JOUR
T1 - Grwoth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75
AU - Szende, Bela
AU - Srkalovic, Gorden
AU - Groot, Kate
AU - Lapis, Karoly
AU - Schally, Andrew V.
N1 - Funding Information:
Received August 24, 1989; revised December 4, 1989; accepted December 12, 1989. Supported by Public Health Service grant CA-40004 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services; and by grants from the Medical Research Service of the Veterans Administration and the G. Harold and Leila Y. Mathers Foundation. A. V. Schally is the recipient of a U.S. Cancer Research Council grant. B. Szende, G. Srkalovic, K. Groot, A. V. Schally, Endocrine, Polypeptide and Cancer Institute, Veterans Administration Medical Center, New Orleans, LA, and Department of Experimental Medicine, Tulane University Medical School, New Orleans, LA. K. Lapis, First Institute of Pathology and Experimental Cancer Research, Semmelweis University Medical School, Budapest, Hungary. We thank Mrs. Elvira Monje, Ms. Illona Janaky, and Mr. Robert O'Brien for experimental assistance. Correspondence lo: Andrew V. Schally, Ph.D., Veterans Administration Medical Center, 1601 Per-dido St., New Orleans, LA 70146.
Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 1990/3/21
Y1 - 1990/3/21
N2 - Female BDF1 mice bearing MXT mammary adenocarcinomas were treated for 3 weeks with the luteinizing hormone-releasing hormone (LH-RH) antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6, D-Ala10]-LH-RH (SB-75), with the agonist D-Trp6-LH-RH, with tamoxifen (5 μg per animal per day subcutaneously), with the combination of D-Trp6-LH-RH and tamoxifen, or by surgical ovariectomy. SB-75 and D-Trp6-LH-RH were administered in the form of microcapsules releasing 25 μg/ day. The reduction in tumor weights after treatment with SB-75, D-Trp6-LH-RH, D-Trp6-LH-RH plus tamoxifen, or ovariectomy was 84%, 64%, 33%, and 67%, respectively. Tamoxifen alone was ineffective. Histologically, the regressive changes in the treated tumors were characteristic of apoptosis (programmed cell death). In view of its potency and its immediate inhibitory effect, the LH-RH antagonist SB-75 should be considered as a possible new hormonal agent for the treatment of breast cancer.
AB - Female BDF1 mice bearing MXT mammary adenocarcinomas were treated for 3 weeks with the luteinizing hormone-releasing hormone (LH-RH) antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6, D-Ala10]-LH-RH (SB-75), with the agonist D-Trp6-LH-RH, with tamoxifen (5 μg per animal per day subcutaneously), with the combination of D-Trp6-LH-RH and tamoxifen, or by surgical ovariectomy. SB-75 and D-Trp6-LH-RH were administered in the form of microcapsules releasing 25 μg/ day. The reduction in tumor weights after treatment with SB-75, D-Trp6-LH-RH, D-Trp6-LH-RH plus tamoxifen, or ovariectomy was 84%, 64%, 33%, and 67%, respectively. Tamoxifen alone was ineffective. Histologically, the regressive changes in the treated tumors were characteristic of apoptosis (programmed cell death). In view of its potency and its immediate inhibitory effect, the LH-RH antagonist SB-75 should be considered as a possible new hormonal agent for the treatment of breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0025262469&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025262469&partnerID=8YFLogxK
U2 - 10.1093/jnci/82.6.513
DO - 10.1093/jnci/82.6.513
M3 - Article
C2 - 2156080
AN - SCOPUS:0025262469
VL - 82
SP - 513
EP - 517
JO - Journal of the National Cancer Institute
JF - Journal of the National Cancer Institute
SN - 0027-8874
IS - 6
ER -
